MANNKIND CORP (MNKD) Stock Fundamental Analysis
USA - NASDAQ:MNKD - US56400P7069 - Common Stock
5.48 USD
-0.11 (-1.97%)
Taking everything into account, MNKD scores 5 out of 10 in our fundamental rating. MNKD was compared to 534 industry peers in the Biotechnology industry. MNKD has only an average score on both its financial health and profitability. MNKD is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year MNKD was profitable.
MNKD had a positive operating cash flow in the past year.
In the past 5 years MNKD reported 4 times negative net income.
In multiple years MNKD reported negative operating cash flow during the last 5 years.
1.2 Ratios
MNKD has a better Return On Assets (7.85%) than 92.88% of its industry peers.
MNKD has a better Return On Invested Capital (21.43%) than 97.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.85% | ||
| ROE | N/A | ||
| ROIC | 21.43% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MNKD's Profit Margin of 10.71% is amongst the best of the industry. MNKD outperforms 92.51% of its industry peers.
MNKD has a Operating Margin of 26.40%. This is amongst the best in the industry. MNKD outperforms 95.88% of its industry peers.
The Gross Margin of MNKD (77.36%) is better than 83.90% of its industry peers.
MNKD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.4% | ||
| PM (TTM) | 10.71% | ||
| GM | 77.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MNKD is creating value.
MNKD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MNKD has been increased compared to 5 years ago.
MNKD has a better debt/assets ratio than last year.
2.2 Solvency
MNKD has an Altman-Z score of -6.78. This is a bad value and indicates that MNKD is not financially healthy and even has some risk of bankruptcy.
MNKD has a Altman-Z score of -6.78. This is in the lower half of the industry: MNKD underperforms 66.48% of its industry peers.
The Debt to FCF ratio of MNKD is 10.09, which is on the high side as it means it would take MNKD, 10.09 years of fcf income to pay off all of its debts.
MNKD has a Debt to FCF ratio of 10.09. This is amongst the best in the industry. MNKD outperforms 91.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 10.09 | ||
| Altman-Z | -6.78 |
ROIC/WACC2.54
WACC8.45%
2.3 Liquidity
MNKD has a Current Ratio of 2.50. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
MNKD has a Current ratio of 2.50. This is in the lower half of the industry: MNKD underperforms 69.10% of its industry peers.
MNKD has a Quick Ratio of 2.24. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
MNKD has a worse Quick ratio (2.24) than 70.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.5 | ||
| Quick Ratio | 2.24 |
3. Growth
3.1 Past
MNKD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 125.00%, which is quite impressive.
Looking at the last year, MNKD shows a very strong growth in Revenue. The Revenue has grown by 21.46%.
The Revenue has been growing by 35.29% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)125%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)21.46%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%5.72%
3.2 Future
MNKD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.96% yearly.
MNKD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.31% yearly.
EPS Next Y18.4%
EPS Next 2Y5.62%
EPS Next 3Y32.25%
EPS Next 5Y43.96%
Revenue Next Year14.19%
Revenue Next 2Y16.74%
Revenue Next 3Y15.12%
Revenue Next 5Y14.31%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
MNKD is valuated quite expensively with a Price/Earnings ratio of 60.89.
91.39% of the companies in the same industry are more expensive than MNKD, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.11, MNKD is valued quite expensively.
Based on the Price/Forward Earnings ratio of 61.40, the valuation of MNKD can be described as expensive.
88.76% of the companies in the same industry are more expensive than MNKD, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.55, MNKD is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 60.89 | ||
| Fwd PE | 61.4 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MNKD is valued cheaply inside the industry as 94.01% of the companies are valued more expensively.
92.13% of the companies in the same industry are more expensive than MNKD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 58.41 | ||
| EV/EBITDA | 18.93 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as MNKD's earnings are expected to grow with 32.25% in the coming years.
PEG (NY)3.31
PEG (5Y)N/A
EPS Next 2Y5.62%
EPS Next 3Y32.25%
5. Dividend
5.1 Amount
No dividends for MNKD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:MNKD (11/3/2025, 1:40:06 PM)
5.48
-0.11 (-1.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners55.89%
Inst Owner Change0.12%
Ins Owners1.51%
Ins Owner Change2.5%
Market Cap1.68B
Revenue(TTM)301.74M
Net Income(TTM)32.32M
Analysts84.62
Price Target10.58 (93.07%)
Short Float %8.34%
Short Ratio5.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-55.44%
Min EPS beat(2)-100%
Max EPS beat(2)-10.87%
EPS beat(4)0
Avg EPS beat(4)-40.95%
Min EPS beat(4)-100%
Max EPS beat(4)-10.87%
EPS beat(8)2
Avg EPS beat(8)-37.57%
EPS beat(12)5
Avg EPS beat(12)-17.45%
EPS beat(16)6
Avg EPS beat(16)-13.49%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-4.55%
Max Revenue beat(2)0.9%
Revenue beat(4)2
Avg Revenue beat(4)-2.76%
Min Revenue beat(4)-7.78%
Max Revenue beat(4)0.9%
Revenue beat(8)5
Avg Revenue beat(8)1.49%
Revenue beat(12)8
Avg Revenue beat(12)4.61%
Revenue beat(16)11
Avg Revenue beat(16)4.15%
PT rev (1m)-1.86%
PT rev (3m)10.67%
EPS NQ rev (1m)-24.99%
EPS NQ rev (3m)-53.12%
EPS NY rev (1m)-12.16%
EPS NY rev (3m)-48.89%
Revenue NQ rev (1m)-3.95%
Revenue NQ rev (3m)0.72%
Revenue NY rev (1m)-1.35%
Revenue NY rev (3m)0.94%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 60.89 | ||
| Fwd PE | 61.4 | ||
| P/S | 5.57 | ||
| P/FCF | 58.41 | ||
| P/OCF | 48.67 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 18.93 |
EPS(TTM)0.09
EY1.64%
EPS(NY)0.09
Fwd EY1.63%
FCF(TTM)0.09
FCFY1.71%
OCF(TTM)0.11
OCFY2.05%
SpS0.98
BVpS-0.18
TBVpS-0.2
PEG (NY)3.31
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.85% | ||
| ROE | N/A | ||
| ROCE | 26.57% | ||
| ROIC | 21.43% | ||
| ROICexc | 45.85% | ||
| ROICexgc | 48.02% | ||
| OM | 26.4% | ||
| PM (TTM) | 10.71% | ||
| GM | 77.36% | ||
| FCFM | 9.54% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
F-Score8
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 10.09 | ||
| Debt/EBITDA | 3.03 | ||
| Cap/Depr | 67.99% | ||
| Cap/Sales | 1.91% | ||
| Interest Coverage | 5.4 | ||
| Cash Conversion | 39.2% | ||
| Profit Quality | 89.07% | ||
| Current Ratio | 2.5 | ||
| Quick Ratio | 2.24 | ||
| Altman-Z | -6.78 |
F-Score8
WACC8.45%
ROIC/WACC2.54
Cap/Depr(3y)397.13%
Cap/Depr(5y)337.1%
Cap/Sales(3y)10.78%
Cap/Sales(5y)10.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y18.4%
EPS Next 2Y5.62%
EPS Next 3Y32.25%
EPS Next 5Y43.96%
Revenue 1Y (TTM)21.46%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%5.72%
Revenue Next Year14.19%
Revenue Next 2Y16.74%
Revenue Next 3Y15.12%
Revenue Next 5Y14.31%
EBIT growth 1Y74.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y150.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y229.39%
OCF growth 3YN/A
OCF growth 5YN/A
MANNKIND CORP / MNKD FAQ
What is the fundamental rating for MNKD stock?
ChartMill assigns a fundamental rating of 5 / 10 to MNKD.
What is the valuation status for MNKD stock?
ChartMill assigns a valuation rating of 5 / 10 to MANNKIND CORP (MNKD). This can be considered as Fairly Valued.
Can you provide the profitability details for MANNKIND CORP?
MANNKIND CORP (MNKD) has a profitability rating of 5 / 10.
Can you provide the expected EPS growth for MNKD stock?
The Earnings per Share (EPS) of MANNKIND CORP (MNKD) is expected to grow by 18.4% in the next year.